Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ('Hims & Hers' or 'the Company') (NYSE: HIMS) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Novo Nordisk issued a press release on June 23, 2025, announcing that it was terminating its 'collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing.' According to the press release, 'the FDA resolved the Wegovy ® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy ® through NovoCare ® Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.' Based on this, shares of Hims & Hers fell by 31.7% in afternoon trading on June 23, 2025.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
26 minutes ago
- Forbes
How To Trade Acuity Stock Ahead Of Earnings
CANADA - 2025/04/14: In this photo illustration, the Acuity logo is seen displayed on a smartphone ... More screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Commercial and industrial lighting firm Acuity (NYSE:AYI) is anticipated to announce its earnings on Thursday, June 26, 2025. According to consensus forecasts, revenue is projected to rise by 18% year-over-year to $1.15 billion, while earnings are expected to be around $4.39 per share, an increase from $4.15 in the same quarter last year. This growth is likely to be partially fueled by the company's acquisition of video and control solutions provider QSC, although it may also be somewhat mitigated by uncertainties in the wider market and challenges associated with tariffs on imports into the U.S. Acuity procures a significant proportion of its lighting products from Asia and Mexico. The company holds a current market capitalization of $8.6 billion. Its revenue for the past twelve months totaled $4.0 billion, and it remained operationally profitable, reporting $546 million in operating profits and a net income of $417 million. That being said, for those seeking upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative – having surpassed the S&P 500 and delivering returns exceeding 91% since its inception. See earnings reaction history of all stocks Acuity's Historical Odds Of Positive Post-Earnings Return Below are some insights regarding one-day (1D) post-earnings returns: Additional information on observed 5-Day (5D) and 21-Day (21D) returns post earnings is compiled along with the statistics in the table below. AYI 1D, 5D, and 21D Post Earnings Return Correlation Between 1D, 5D, and 21D Historical Returns A relatively lower-risk strategy (although not helpful if the correlation is weak) is to examine the relationship between short-term and medium-term returns after earnings, identify a pair that exhibits the highest correlation, and undertake the suitable trade. For instance, if 1D and 5D display the highest correlation, a trader might choose to go "long" for the following 5 days if the 1D post-earnings return is positive. Here are some correlation statistics based on five-year and three-year (more recent) data. Note that the correlation 1D_5D refers to the relationship between 1D post-earnings returns and subsequent 5D returns. AYI Correlation Between 1D, 5D, and 21D Historical Returns Discover more about the Trefis RV strategy that has outperformed its all-cap stocks benchmark (which is a mix of all three—the S&P 500, S&P mid-cap, and Russell 2000)—to generate strong returns for investors. Additionally, if you are seeking upside with a more stable experience than investing in an individual stock like Acuity, consider the High Quality portfolio, which has outperformed the S&P and achieved returns greater than 91% since inception.
Associated Press
27 minutes ago
- Associated Press
Zomedica Announces Issuance of Additional Patent for its TRUVIEW(R) Microscope
Intellectual Property Portfolio grows to 221 Patents and 140 Trademarks ANN ARBOR, MI / ACCESS Newswire / June 24, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ('Zomedica' or the 'Company'), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the issuance of a new patent related to its TRUVIEW microscope and provided an update on the Company's current intellectual property portfolio. The U.S. Patent related to the TRUVIEW microscope, manufactured, sold and distributed by Zomedica, was U.S. Patent No. 12,299,917 B2 issued recently for the Methods and Systems for Slide Imaging Calibration. Bill Campbell, Zomedica's Vice President of Imaging Systems and inventor of the TRUVIEW microscope, stated, 'Securing this patent is a significant milestone that underscores our commitment to innovation in digital microscopy. This protection not only validates the uniqueness of our focusing system but also strengthens our position as a leader in imaging solutions. We are excited about the possibilities this opens for enhancing image quality and usability in clinical applications. With the addition of this recently issued patent, Zomedica's IP portfolio now includes 77 issued U.S. patents and 144 issued international patents as well as 33 registered U.S. trademarks and 107 registered foreign trademarks related to its therapeutic device and diagnostic products. Larry Heaton, Chief Executive Officer of Zomedica stated, 'We are pleased to add this patent protecting our innovative TRUVIEW device to our growing portfolio. The Zomedica Research & Development team has been actively expanding our intellectual property portfolio through ongoing development of our innovative products. This protection enables us to devote resources to investing in growing new markets for our unique products, knowing that Zomedica's highly differentiated proprietary products will remain unique.' About Zomedica Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $65 million in liquidity as of March 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit Follow Zomedica Cautionary Note Regarding Forward-Looking Statements Except for statements of historical fact, this news release contains certain 'forward-looking information' or 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as 'plan', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate' and other similar words, or statements that certain events or conditions 'may' or 'will' occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Investor Relations Contact: Zomedica Investor Relations [email protected] 1-734-369-2555 SOURCE: Zomedica Corp. press release
Associated Press
27 minutes ago
- Associated Press
NUTEX HEALTH INC. ADDED TO RUSSELL 3000® INDEX AND RUSSELL MICROCAP® INDEX
HOUSTON, June 24, 2025 /PRNewswire/ -- Nutex Health Inc. ('Nutex Health' or the 'Company') (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced it has been added as a member of the broad-market Russell 3000® Index and the Russell Microcap® Index, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. 'Inclusion in the Russell Indexes is great validation of the Nutex Health business model and will help increase our visibility with long term institutional investors,' stated Jon Bates, Chief Financial Officer of Nutex Health. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website. About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division. The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit FTSE Russell. Forward-Looking Statements Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will', 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' 'goal,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, under the heading 'Risk Factors' in Part II, Item IA thereof, and the risk factors and other cautionary statements contained in our other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. View original content: SOURCE Nutex Health, Inc.
